ORYZON announces U.S. FDA clearance of CTEP-CRADA Phase I/II clinical trial sponsored by NCI for iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer

by Oryzon Genomics

Oryzon Genomics announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate a Phase I/II trial with iadademstat plus immune...

Read more

ORYZON to provide corporate progress updates at several events in April

by Oryzon Genomics

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...

Read more

ORYZON receives the INNOVATIVE SME seal from the Spanish Ministry of Science and Innovation

by Oryzon Genomics
  • 16 days ago

Oryzon Genomics, S.A. announces that it has obtained the INNOVATIVE SME seal from the Spanish Ministry of Science and Innovation, and has consequently been registered in the Public Registry of INNOVAT...

Read more

ORYZON reports financial results and corporate update for quarter ended December 31, 2023

by Oryzon Genomics

yzon Genomics, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reported financial results for the fourth quar...

Read more

ORYZON to provide corporate progress updates at several events in February-March

by Oryzon Genomics

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...

Read more

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

by Oryzon Genomics

Oryzon Genomics today announced that it will host a virtual KOL event to review and discuss the topline results from the Phase IIb PORTICO study evaluating vafidemstat in Borderline Personality Disord...

Read more

ORYZON Announces Topline Results from Phase IIb PORTICO study of vafidemstat in Borderline Personality Disorder (BPD)

by Oryzon Genomics

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced topline results from the Pha...

Read more

ORYZON to provide corporate progress updates at several events in January

by Oryzon Genomics

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...

Read more

ORYZON entre las 1000 empresas europeas con mayor inversión en I+D

by Oryzon Genomics

Oryzon Genomics S.A. se complace en compartir que, de acuerdo al ranking publicado por la Unión Europea, se encuentra entre las 1000 empresas europeas con mayor inversión en I+D, en concreto en la p...

Read more

ORYZON awarded with a grant for ORY-4001 from the ALS Association in the U.S

by Oryzon Genomics

The Association has awarded Oryzon a 498,690 USD grant through its Lawrence and Isabel Barnett Drug Development Program to support the regulatory preclinical development of ORY-4001, a highly selectiv...

Read more

ORYZON announces a New Financing through a Convertible Bond Program for a total amount of up to €45 million

by Oryzon Genomics

Funding provided by Nice & Green SA, a Swiss private investor, of €8 million in two tranches of €4 million each, plus optional additional tranches of up to €5 million each to be executed in the ...

Read more

ORYZON announces Last Patient Last Visit in its Phase IIb PORTICO study for Borderline Personality Disorder (BPD)

by Oryzon Genomics

Oryzon Genomics, S.A. today announced Last Patient Last Visit in its ongoing Phase IIb PORTICO trial, investigating vafidemstat’s efficacy in Borderline Personality Disorder (BPD). Multiple primary ...

Read more
Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Palobiofarma announces the completion th...

by Palobiofarma

Palobiofarma S.L. is pleased to announce the “last patient last visi...

Photos Stream